1. Home
  2. LIVN vs WLYB Comparison

LIVN vs WLYB Comparison

Compare LIVN & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIVN
  • WLYB
  • Stock Information
  • Founded
  • LIVN 1987
  • WLYB 1807
  • Country
  • LIVN United Kingdom
  • WLYB United States
  • Employees
  • LIVN N/A
  • WLYB N/A
  • Industry
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • WLYB Books
  • Sector
  • LIVN Health Care
  • WLYB Consumer Discretionary
  • Exchange
  • LIVN Nasdaq
  • WLYB Nasdaq
  • Market Cap
  • LIVN 2.2B
  • WLYB 2.3B
  • IPO Year
  • LIVN 1993
  • WLYB N/A
  • Fundamental
  • Price
  • LIVN $35.58
  • WLYB N/A
  • Analyst Decision
  • LIVN Buy
  • WLYB
  • Analyst Count
  • LIVN 7
  • WLYB 0
  • Target Price
  • LIVN $60.29
  • WLYB N/A
  • AVG Volume (30 Days)
  • LIVN 772.6K
  • WLYB 1.2K
  • Earning Date
  • LIVN 05-07-2025
  • WLYB 06-12-2025
  • Dividend Yield
  • LIVN N/A
  • WLYB 3.28%
  • EPS Growth
  • LIVN 262.50
  • WLYB N/A
  • EPS
  • LIVN 1.16
  • WLYB 0.75
  • Revenue
  • LIVN $1,253,437,000.00
  • WLYB $1,703,491,000.00
  • Revenue This Year
  • LIVN $5.79
  • WLYB N/A
  • Revenue Next Year
  • LIVN $5.35
  • WLYB $1.13
  • P/E Ratio
  • LIVN $30.67
  • WLYB $55.86
  • Revenue Growth
  • LIVN 8.66
  • WLYB N/A
  • 52 Week Low
  • LIVN $32.48
  • WLYB $35.68
  • 52 Week High
  • LIVN $64.48
  • WLYB $52.90
  • Technical
  • Relative Strength Index (RSI)
  • LIVN 40.50
  • WLYB 50.41
  • Support Level
  • LIVN $32.65
  • WLYB $39.54
  • Resistance Level
  • LIVN $35.89
  • WLYB $43.04
  • Average True Range (ATR)
  • LIVN 1.91
  • WLYB 0.38
  • MACD
  • LIVN 0.05
  • WLYB -0.16
  • Stochastic Oscillator
  • LIVN 42.70
  • WLYB 61.57

About LIVN LivaNova PLC

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: